3 Healthcare Stocks With Long Growth Runways

Three healthcare stocks with long growth runways could lift the sector to greater heights in 2023 and beyond.

| More on:
A doctor takes a patient's blood pressure in a clinical office.

Source: Getty Images

The healthcare sector has performed poorly in recent years, including the COVID year in 2020. Surprisingly, as of this writing, it outperforms all sectors with its 11.95% year-to-date gain.

A reversal of fortune might be on the horizon, especially for growth stocks like Bausch Health Companies (TSX:BHC), Andlauer Healthcare Group (TSX:AND), and Neighbourly Pharmacy (TSX:NBLY).

Extensive product pipeline

Bausch Health develops, manufactures, and markets a range of products in dermatology, gastroenterology, hepatology, neurology, and international pharmaceuticals. It offers a broad range of branded and generic pharmaceuticals, including over-the-counter (OTC) products. Moreover, the global reach extends from North America to several geographic regions.

Current investors delight in the stock’s strong start in 2023 and the 19.53% advance to $10.06 from year-end 2022. Market analysts’ high price target in 12 months is $18.76 — an 86.5% return potential.

The $3.67 billion diversified pharmaceutical company derives health revenues from five segments. According to management, the product pipeline and portfolio expansion reflect Bausch’s commitment to developing innovative products that can help improve people’s lives.

Specialized services

Andlauer Healthcare Group, or AHG, flies under the radar, but it deserves attention following the impressive financial results after three quarters in 2022. Also, at $47.20 per share (-0.32% year to date), this healthcare stock pays a modest 0.59% dividend. Based on market analysts’ forecasts, the price could climb to as high as $60 in 12 months.

In the nine months that ended September 30, 2022, total revenue and net income jumped 57.2% and 53.2% year over year to $482.65 million and $56.45 million, respectively. The top- and bottom-line growth in the third quarter of 2022 were 58.3% and 55.9%. Notably, ground transportation reported the most significant percentage increases in revenue and income.

Its chief executive officer (CEO) Michael Andlauer said, “Our strong growth in revenue and profitability in the quarter and year-to-date reflects the significant impact of our recent acquisitions in both our healthcare logistics and specialized transportation segments.” The full-year 2022 results will come soon, although Andlauer expects to report solid earnings momentum and a strong balance sheet.

AHG takes pride in its robust platform of customized third-party logistics and specialized transportation solutions for the healthcare sector. The $1.97 billion growth-oriented supply chain management company plans to seize further opportunities to expand its North American platform and build value for stakeholders.

Healthcare first

Neighbourly Pharmacy is about community pharmacies and a “healthcare first” strategy that drives performance. The $1.03 billion company desires to be the leader in community healthcare and is on track to achieve that objective. It’s now Canada’s largest and fastest-growing network of independent pharmacies.

Management entered into two binding agreements in October 2022 to acquire eight community pharmacies. The locations of the pharmacies are primarily in smaller, underserved markets, favouring Neighbourly. Apart from generating the bulk of revenues from prescription sales, the competition is less intense.

Neighbourly is also a dividend payer. At $23.30 per share (-0.38% year to date), the dividend yield is 0.77%.

Long growth runways

Bausch Health, Andlauer Healthcare, and Neighbourly Pharmacy have one common denominator: a long growth runway. The companies have catalysts that should propel their stock prices higher in the near term.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Andlauer Healthcare Group. The Motley Fool has a disclosure policy.

More on Dividend Stocks

protect, safe, trust
Dividend Stocks

Worried About a Recession? 2 TSX Blue-Chip Stocks to Protect Your Capital

If you fear a recession coming on soon, here are two blue-chip Canadian stocks to add to your portfolio for…

Read more »

Silver coins fall into a piggy bank.
Dividend Stocks

New TFSA Investors: 2 Top TSX Stock to Create a Self-Directed Retirement Fund

Top TSX dividend stocks are now on sale for new TFSA investors.

Read more »

money while you sleep
Dividend Stocks

Worried About the Market? 2 Dividend Stocks That Let You Sleep at Night

Here's why Restaurant Brands (TSX:QSR) and Enbridge (TSX:ENB) are two top dividend stocks to buy in this uncertain market right…

Read more »

money cash dividends
Dividend Stocks

How 1 Absurdly Cheap Stock Can Generate $100 in Monthly Passive Income

You can generate $100 or more in monthly passive income from one high-yield stock trading at an absurdly cheap price…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

How I’d Invest $1000 in February to Make Easy Passive Income

Looking to earn some extra passive income in February but don't have much cash? Build an easy portfolio with these…

Read more »

sad concerned deep in thought
Dividend Stocks

Is it Worth Investing in Rogers or Shaw Before the Pending Merger?

A Rogers stock and Shaw stock deal looks all but certain, yet should investors still buy the stock? Or are…

Read more »

runner ties shoe while stopped on grass outside
Dividend Stocks

Is Nutrien Stock a Buy in February 2023?

Nutrien stock should benefit from the very favourable supply/demand fundamentals in the agriculture business in 2023.

Read more »

thinking
Dividend Stocks

Is Brookfield Asset Management a Buy in February 2023?

Brookfield Asset Management is among the largest stocks trading on the TSX. Let's see why BAM stock is a buy…

Read more »